Absolutely agree. For me, this is the most important technical issue for us. The inhibition of NGF is an one part of the puzzle understood but the other one is around cartilage regeneration/repair. How does that work? If we really understood these and were able to screen patients for efficacy based on tests derived from this understanding then our FDA pathway would be very smooth.
Ann: Paradigm to present at NWR Virtual Conference, page-34
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 20.5¢ | $222.5K | 1.035M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 77810 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 23000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |